Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes

Baricitinib is a Janus kinase (JAK) 1 and 2 inhibitor approved for treating rheumatoid arthritis (RA). The JAK/STAT system is essential in the intracellular signaling of different cytokines and in the activation process of the monocyte lineage. This study verifies the effects of baricitinib on STAT...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gloria Tucci, Cristina Garufi, Ilenia Pacella, Marta Zagaglioni, Alessandra Pinzon Grimaldos, Fulvia Ceccarelli, Fabrizio Conti, Francesca Romana Spinelli, Silvia Piconese
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-07-01
coleção:	Frontiers in Immunology
Assuntos:	interferon STAT JAKi monocytes rheumatoid arthritis ISGs
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.932240/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!